Date: 2015-10-07
Type of information: Licensing agreement
Compound: selected cytokines for ex vivo cell culture therapy applications
Company: CEVEC Pharmaceuticals (Germany) CellGenix (Germany)
Therapeutic area: Technology - Services
Type agreement: development licensing
Action mechanism:
Disease:
Details: * On October 7, 2015, CEVEC Pharmaceuticals, a company specialized in the production of tailor-made recombinant glycoproteins and gene therapy vectors, and CellGenix, a manufacturer of premium-grade reagents for clinical cell culture needs, announced a collaboration and license agreement for the development and GMP production of selected cytokines for ex vivo cell culture therapy applications using CEVEC's proprietary CAP®Go technology.
Under the terms of the agreement, CEVEC offers its expertise regarding the development of selected CAP®Go cell lines as well as its competence for the expression of a variety of difficult to produce recombinant cytokines. In addition the company will grant CellGenix a license for the production and commercialization of CAP®Go-derived growth and differentiation factors.
CellGenix will provide its long-standing expertise in development of high-quality recombinant ex vivo reagents. In addition the company will use its in-house GMP manufacturing capabilities, established Quality Assurance system as well as its expert regulatory know-how to ensure compliance of CAP®Go-derived products with the complex regulatory landscape for cell-based therapies. The products will be marketed by CellGenix and expand the existing portfolio of GMP-grade cell culture systems to develop preclinical and clinical cell therapies.
Financial terms: Financial details of this agreement were not disclosed.
Latest news:
